SCHEMBL5040445

SCHEMBL5040445

Cc1ccc(S(=O)(=O)Nc2cc[c]cc2)cc1Cl

nearest known ligand 0.61

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
PKM P14618 6/20 0.53
MEN1 O00255 3/20 0.50
KMT2A Q03164 3/20 0.50
MAPT P10636 4/20 0.49
TDP1 Q9NUW8 1/20 0.49
IDH1 O75874 1/20 0.47
FLT1 P17948 1/20 0.46
FLT4 P35916 1/20 0.46
KDR P35968 1/20 0.46
LMNA P02545 2/20 0.46
PGR P06401 1/20 0.46
TP53 P04637 1/20 0.46
ALDH1A1 P00352 1/20 0.45
THRB P10828 1/20 0.45
HTT P42858 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5046807 0.86 MAPT (0.58) MEN1KMT2AMAPTLMNAPGR
SCHEMBL5046805 0.83 PKM (0.49) PKMMEN1KMT2AMAPTTDP1
SCHEMBL95688 0.82 PKM (0.60) PKMMEN1KMT2AMAPTTDP1
SCHEMBL23228007 0.82 MEN1 (0.54) PKMMEN1KMT2AMAPTIDH1
SCHEMBL161523 0.78 LMNA (0.46) MAPTFLT1FLT4KDRLMNA
SCHEMBL3277692 0.77 CA12 (0.68) MEN1KMT2AMAPTTDP1LMNA
SCHEMBL4142277 0.77 CES1 (0.75) MAPTTDP1PGRALDH1A1HTT
SCHEMBL8037282 0.75 LMNA (0.65) PKMMEN1KMT2AMAPTFLT1
SCHEMBL17174222 0.75 CES1 (0.66) PKMMEN1KMT2AMAPTTDP1
SCHEMBL5041089 0.75 KMT2A (0.68) MEN1KMT2AMAPTLMNAPGR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1250325-B1 PHENANTHRIDINE-N-OXIDES NYCOMED GMBH (DE) 2008-05-07 EP disclosed
US-6630483-B2 Phenanthridine-N-oxides ALTANA PHARMA AG (DE) 2003-10-07 US disclosed
US-20030105123-A1 For therapy of respiratory system disorders ALTANA PHARMA AG (DE) 2003-06-05 US disclosed
EP-0889886-B1 NOVEL PHENANTHRIDINES SUBSTITUTED IN THE 6 POSITION ALTANA PHARMA AG (DE) 2002-09-18 EP disclosed
US-6127378-A A PHOSPHODIESTERASE ENZYME INHIBITOR AS BRONCHIAL THERAPEUTICS, AN ANTIINFLAMMATORY AGENT TREATING ASTHMA PROPHYLAXIS, SKIN DISORDERS, INTESTINE DISORDERS, EYE DISORDERS, CENTRAL NERVOUS SYSTEM DISORDERS, JOINTS DISORDERS BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) 2000-10-03 US disclosed
EP-0889886-A1 NOVEL PHENANTHRIDINES SUBSTITUTED IN THE 6 POSITION Byk Gulden Lomberg Chemische Fabrik GmbH (DE) 1999-01-13 EP disclosed
WO-1997035854-A1 NOVEL PHENANTHRIDINES SUBSTITUTED IN THE 6 POSITION BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) 1997-10-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030105123-A1 For therapy of respiratory system disorders CHRM3, CYP11B1, CYP11B2 PKM 1732/4885MEN1 3969/4885KMT2A 3871/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.